Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  elotuzumab
Find trials that include:  Any drugs shown
Results 1-8 of 8 for your search:
Start Over
Study of Combinations of Nivolumab, Elotuzumab, Pomalidomide and Dexamethasone in Multiple Myeloma
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: CA209-602, NCI-2016-00875, 2015-005699-21, NCT02726581
Bortezomib, Dexamethasone, and Lenalidomide with or without Elotuzumab in Treating Patients with Newly Diagnosed High-Risk Multiple Myeloma
Status: Temporarily closed
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: S1211, NCI-2012-01998, CDR0000738512, PS1211_A12PAMDREVW01, SWOG-S1211, NCT01668719
Elotuzumab and Lenalidomide with or without Dexamethasone in Treating Patients with High-Risk Smoldering Multiple Myeloma
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 14-338, NCI-2014-02644, CA 204-119, CA 204-119 (BMS), RV-CL-MM-PI-004473 (Celgene), RV-CL- MM-PI-004473, NCT02279394
Bortezomib, Lenalidomide, Dexamethasone and Elotuzumab in Treating Patients with Newly Diagnosed Multiple Myeloma
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 14-453, NCI-2015-00898, NCT02375555
Elotuzumab and Lenalidomide after Stem Cell Transplant in Treating Patients with Newly Diagnosed Multiple Myeloma
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 2014-0729, NCI-2015-00762, NCT02420860
Elotuzumab, Pomalidomide, Bortezomib, and Dexamethasone in Treating Patients with Relapsed or Refractory Multiple Myeloma
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 15-475, NCI-2016-00943, NCT02718833
Trial of Pomalidomide and Low-dose Dexamethasone With or Without Elotuzumab to Treat Refractory and Relapsed and Refractory Multiple Myeloma (ELOQUENT-3)
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: CA204-125, NCI-2016-01039, 2014-003282-19, NCT02654132
Start Over